Independent Advisor Alliance Cuts Stock Holdings in Boston Scientific Corporation $BSX

Independent Advisor Alliance lessened its stake in Boston Scientific Corporation (NYSE:BSX) by 52.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 17,474 shares of the medical equipment provider’s stock after selling 19,486 shares during the quarter. Independent Advisor Alliance’s holdings in Boston Scientific were worth $1,666,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in BSX. Murphy & Mullick Capital Management Corp grew its position in Boston Scientific by 200.0% during the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 170 shares during the period. FWL Investment Management LLC purchased a new position in shares of Boston Scientific in the 2nd quarter worth about $26,000. United Community Bank raised its holdings in shares of Boston Scientific by 115.7% in the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 147 shares during the period. Colonial Trust Co SC lifted its stake in shares of Boston Scientific by 502.2% in the 3rd quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 231 shares in the last quarter. Finally, Bangor Savings Bank grew its holdings in shares of Boston Scientific by 94.7% during the 4th quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 142 shares during the period. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Stock Down 1.7%

Shares of NYSE:BSX opened at $52.67 on Friday. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42. Boston Scientific Corporation has a 52-week low of $52.52 and a 52-week high of $109.50. The company has a 50 day moving average of $63.40 and a two-hundred day moving average of $81.79. The company has a market capitalization of $78.27 billion, a price-to-earnings ratio of 22.04, a price-to-earnings-growth ratio of 0.98 and a beta of 0.62.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. The business had revenue of $5.20 billion for the quarter, compared to analysts’ expectations of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The business’s revenue for the quarter was up 11.6% compared to the same quarter last year. During the same period in the previous year, the company posted $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, analysts forecast that Boston Scientific Corporation will post 3.38 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently commented on BSX. Royal Bank Of Canada cut their price target on shares of Boston Scientific from $105.00 to $100.00 and set an “outperform” rating on the stock in a report on Thursday, April 23rd. BTIG Research decreased their price objective on shares of Boston Scientific from $90.00 to $80.00 and set a “buy” rating for the company in a research note on Wednesday, April 22nd. Mizuho dropped their price objective on shares of Boston Scientific from $115.00 to $90.00 and set an “outperform” rating for the company in a research report on Monday, April 13th. Needham & Company LLC reduced their target price on shares of Boston Scientific from $97.00 to $77.00 and set a “buy” rating on the stock in a report on Thursday, April 23rd. Finally, Weiss Ratings cut shares of Boston Scientific from a “hold (c)” rating to a “hold (c-)” rating in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, Boston Scientific presently has an average rating of “Moderate Buy” and an average price target of $93.91.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.